Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with…
Enhertu demonstrates improvement in invasive DFS in HER2+ breast cancer after neoadjuvant therapy
